8-K current report · filed Nov 13, 2026

Benitec Biopharma Inc. (BNTC) 8-K Current Report: November 13, 2026

Item 2.02Item 5.03Item EX-99.1BNTC overview

Short answer

Benitec Biopharma Inc. (BNTC) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item EX-99.1 (Exhibit EX-99.1). Fiscal-quarter results for period ended September 30, 2026 announced.

Benitec Biopharma Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Fiscal-quarter results for period ended September 30, 2026 announced
  • Operational update accompanies financial results
  • Press release provided as Exhibit 99.1, containing the detailed figures and commentary

Item 5.03 · Amendments to Articles of Incorporation or Bylaws

  • Fiscal year-end shifted from June 30 to December 31, effective November 12, 2026
  • Six-month transition period, July 1 through December 31, 2026, reported in a Transition Form 10-K
  • Calendar-year reporting begins January 1, 2027, improving period comparability
  • No Articles of Incorporation or Bylaws amendment required

Item EX-99.1 · Exhibit EX-99.1

  • BB-301 interim data showed a 100% responder rate across six Cohort 1 and three Cohort 2 patients, with no serious adverse events reported
  • Pivotal BB-301 study design targeted for Q1 2027, with trial initiation still planned for mid-2027
  • Cash and equivalents $176.5 million at September 30, 2026, supporting continued development but not eliminating future financing risk
  • R&D expense rose to $8.6 million from $3.4 million, reflecting accelerated BB-301 clinical investment
  • Net loss widened to $12.9 million from $9.0 million, while shares outstanding increased to 49.5 million from 41.5 million weighted-average shares

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Benitec Biopharma Inc. 8-K filings

Get the next BNTC 8-K as it lands

Follow BNTC for push alerts, or ask the research agent what this filing means.